Table 1. Single (unpaired) samples used in IgG subclass comparisons, and clinical status of the Indian and Sudanese patient groups.

	VL patient status					Controls
Unpaired group	Active	Cured	Relapsed	Treateda	PKDL	Other diseases	EHC (seropositive)	EHC (seronegative)
Trial 1 India	20	21	19	-	-	20	-	20
Trial 2 (Expanded) India	46	28	35	-	24	28	28	32
Trial Sudan	47	-	-	22	23	-	30	12

EHC = endemic healthy control; PKDL = post kala-azar dermal leishmaniasis.

^atreated, not in recent past, but time of treatment unknown.